Cyclizine is a defined chemical entity of pharmaceutical relevance whose identity, purity, and physicochemical properties are specified per ICH Q6A standards or equivalent pharmacopoeial monograph requirements. Its solubility, lipophilicity, and ionisation state govern formulation compatibility, bioavailability, and environmental distribution behaviour. PDE derivation for Cyclizine requires systematic review of acute, repeat-dose, genotoxicity, reproductive toxicity, and carcinogenicity data, identifying the most sensitive adverse effect endpoint and the species-specific NOAEL that forms the point of departure for calculation.
Cleaning validation acceptance criteria for Cyclizine in shared pharmaceutical equipment are determined using the health-based MACO formula: MACO (mg/batch) = PDE(mg/day) × MBS(g) ÷ TDD(g/day), where MBS is the minimum batch size of the next product and TDD its maximum daily therapeutic dose.
